Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | bone marrow |
| Expression Pattern | down-regulated |
| Function Description | MEG3 expression was lower in AML patients than in the controls (P = 0.136). Moreover, there was greater methylation of MEG3 promoter in the AML patients than the controls (P < 0.05). hese results suggest that hypermethylation of the MEG3 promoter in AML may result from decreased TET2 activity. |
| Pubmed ID | 28407691 |
| Year | 2017 |
| Title | TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |